Screening for hepatocellular carcinoma in chronic liver disease: A systematic review

Devan Kansagara, Joel Papak, Amirala S. Pasha, Maya O'Neil, Michele Freeman, Rose Relevo, Ana Quinones, Makalapua Motu'apuaka, Janice Jou

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Guidelines recommend routine screening for hepatocellular carcinoma (HCC) in high-risk patients, but the strength of evidence supporting these recommendations is unclear. Purpose: To review the benefits and harms of HCC screening in patients with chronic liver disease. Data Sources: MEDLINE, PsycINFO, and ClinicalTrials.gov from inception to April 2014; Cochrane databases to June 2013; reference lists; and technical advisors. Study Selection: English-language trials and observational studies comparing screening versus no screening, studies of harms, and trials comparing different screening intervals. Data Extraction: Mortality and adverse events were the outcomes of interest. Individual-study quality and the overall strength of evidence were dual-reviewed using published criteria. Data Synthesis: Of 13 801 citations, 22 studies met inclusion criteria. The overall strength of evidence on the effects of screening was very low. One large trial of patients with hepatitis B found decreased HCC mortality with periodic ultrasonographic screening (rate ratio, 0.63 [95% CI, 0.41 to 0.98]), but the study was limited by methodological flaws. Another trial in patients with hepatitis B found no survival benefit with periodic α-fetoprotein screening. In 18 observational studies, screened patients had earlier-stage HCC than clinically diagnosed patients, but lead- and length-time biases confounded the effects on mortality. Two trials found no survival differences between shorter (3- to 4-month) and longer (6- to 12-month) screening intervals. Harms of screening were not well-studied. Limitations: Only English-language studies were included. The evidence base is limited by methodological issues and a paucity of trials. Conclusion: There is very-low-strength evidence about the effects of HCC screening on mortality in patients with chronic liver disease. Screening tests can identify early-stage HCC, but whether systematic screening leads to a survival advantage over clinical diagnosis is uncertain.

Original languageEnglish (US)
Pages (from-to)261-269
Number of pages9
JournalAnnals of Internal Medicine
Volume161
Issue number4
DOIs
StatePublished - Aug 19 2014

Fingerprint

Liver Diseases
Hepatocellular Carcinoma
Chronic Disease
Mortality
Hepatitis B
Observational Studies
Survival
Language
Fetal Proteins
Information Storage and Retrieval
MEDLINE
Databases
Guidelines

ASJC Scopus subject areas

  • Internal Medicine
  • Medicine(all)

Cite this

Screening for hepatocellular carcinoma in chronic liver disease : A systematic review. / Kansagara, Devan; Papak, Joel; Pasha, Amirala S.; O'Neil, Maya; Freeman, Michele; Relevo, Rose; Quinones, Ana; Motu'apuaka, Makalapua; Jou, Janice.

In: Annals of Internal Medicine, Vol. 161, No. 4, 19.08.2014, p. 261-269.

Research output: Contribution to journalArticle

Kansagara, Devan ; Papak, Joel ; Pasha, Amirala S. ; O'Neil, Maya ; Freeman, Michele ; Relevo, Rose ; Quinones, Ana ; Motu'apuaka, Makalapua ; Jou, Janice. / Screening for hepatocellular carcinoma in chronic liver disease : A systematic review. In: Annals of Internal Medicine. 2014 ; Vol. 161, No. 4. pp. 261-269.
@article{33ca1d2e7746417e979d36b61c72f677,
title = "Screening for hepatocellular carcinoma in chronic liver disease: A systematic review",
abstract = "Guidelines recommend routine screening for hepatocellular carcinoma (HCC) in high-risk patients, but the strength of evidence supporting these recommendations is unclear. Purpose: To review the benefits and harms of HCC screening in patients with chronic liver disease. Data Sources: MEDLINE, PsycINFO, and ClinicalTrials.gov from inception to April 2014; Cochrane databases to June 2013; reference lists; and technical advisors. Study Selection: English-language trials and observational studies comparing screening versus no screening, studies of harms, and trials comparing different screening intervals. Data Extraction: Mortality and adverse events were the outcomes of interest. Individual-study quality and the overall strength of evidence were dual-reviewed using published criteria. Data Synthesis: Of 13 801 citations, 22 studies met inclusion criteria. The overall strength of evidence on the effects of screening was very low. One large trial of patients with hepatitis B found decreased HCC mortality with periodic ultrasonographic screening (rate ratio, 0.63 [95{\%} CI, 0.41 to 0.98]), but the study was limited by methodological flaws. Another trial in patients with hepatitis B found no survival benefit with periodic α-fetoprotein screening. In 18 observational studies, screened patients had earlier-stage HCC than clinically diagnosed patients, but lead- and length-time biases confounded the effects on mortality. Two trials found no survival differences between shorter (3- to 4-month) and longer (6- to 12-month) screening intervals. Harms of screening were not well-studied. Limitations: Only English-language studies were included. The evidence base is limited by methodological issues and a paucity of trials. Conclusion: There is very-low-strength evidence about the effects of HCC screening on mortality in patients with chronic liver disease. Screening tests can identify early-stage HCC, but whether systematic screening leads to a survival advantage over clinical diagnosis is uncertain.",
author = "Devan Kansagara and Joel Papak and Pasha, {Amirala S.} and Maya O'Neil and Michele Freeman and Rose Relevo and Ana Quinones and Makalapua Motu'apuaka and Janice Jou",
year = "2014",
month = "8",
day = "19",
doi = "10.7326/M14-0558",
language = "English (US)",
volume = "161",
pages = "261--269",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "4",

}

TY - JOUR

T1 - Screening for hepatocellular carcinoma in chronic liver disease

T2 - A systematic review

AU - Kansagara, Devan

AU - Papak, Joel

AU - Pasha, Amirala S.

AU - O'Neil, Maya

AU - Freeman, Michele

AU - Relevo, Rose

AU - Quinones, Ana

AU - Motu'apuaka, Makalapua

AU - Jou, Janice

PY - 2014/8/19

Y1 - 2014/8/19

N2 - Guidelines recommend routine screening for hepatocellular carcinoma (HCC) in high-risk patients, but the strength of evidence supporting these recommendations is unclear. Purpose: To review the benefits and harms of HCC screening in patients with chronic liver disease. Data Sources: MEDLINE, PsycINFO, and ClinicalTrials.gov from inception to April 2014; Cochrane databases to June 2013; reference lists; and technical advisors. Study Selection: English-language trials and observational studies comparing screening versus no screening, studies of harms, and trials comparing different screening intervals. Data Extraction: Mortality and adverse events were the outcomes of interest. Individual-study quality and the overall strength of evidence were dual-reviewed using published criteria. Data Synthesis: Of 13 801 citations, 22 studies met inclusion criteria. The overall strength of evidence on the effects of screening was very low. One large trial of patients with hepatitis B found decreased HCC mortality with periodic ultrasonographic screening (rate ratio, 0.63 [95% CI, 0.41 to 0.98]), but the study was limited by methodological flaws. Another trial in patients with hepatitis B found no survival benefit with periodic α-fetoprotein screening. In 18 observational studies, screened patients had earlier-stage HCC than clinically diagnosed patients, but lead- and length-time biases confounded the effects on mortality. Two trials found no survival differences between shorter (3- to 4-month) and longer (6- to 12-month) screening intervals. Harms of screening were not well-studied. Limitations: Only English-language studies were included. The evidence base is limited by methodological issues and a paucity of trials. Conclusion: There is very-low-strength evidence about the effects of HCC screening on mortality in patients with chronic liver disease. Screening tests can identify early-stage HCC, but whether systematic screening leads to a survival advantage over clinical diagnosis is uncertain.

AB - Guidelines recommend routine screening for hepatocellular carcinoma (HCC) in high-risk patients, but the strength of evidence supporting these recommendations is unclear. Purpose: To review the benefits and harms of HCC screening in patients with chronic liver disease. Data Sources: MEDLINE, PsycINFO, and ClinicalTrials.gov from inception to April 2014; Cochrane databases to June 2013; reference lists; and technical advisors. Study Selection: English-language trials and observational studies comparing screening versus no screening, studies of harms, and trials comparing different screening intervals. Data Extraction: Mortality and adverse events were the outcomes of interest. Individual-study quality and the overall strength of evidence were dual-reviewed using published criteria. Data Synthesis: Of 13 801 citations, 22 studies met inclusion criteria. The overall strength of evidence on the effects of screening was very low. One large trial of patients with hepatitis B found decreased HCC mortality with periodic ultrasonographic screening (rate ratio, 0.63 [95% CI, 0.41 to 0.98]), but the study was limited by methodological flaws. Another trial in patients with hepatitis B found no survival benefit with periodic α-fetoprotein screening. In 18 observational studies, screened patients had earlier-stage HCC than clinically diagnosed patients, but lead- and length-time biases confounded the effects on mortality. Two trials found no survival differences between shorter (3- to 4-month) and longer (6- to 12-month) screening intervals. Harms of screening were not well-studied. Limitations: Only English-language studies were included. The evidence base is limited by methodological issues and a paucity of trials. Conclusion: There is very-low-strength evidence about the effects of HCC screening on mortality in patients with chronic liver disease. Screening tests can identify early-stage HCC, but whether systematic screening leads to a survival advantage over clinical diagnosis is uncertain.

UR - http://www.scopus.com/inward/record.url?scp=84907326817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907326817&partnerID=8YFLogxK

U2 - 10.7326/M14-0558

DO - 10.7326/M14-0558

M3 - Article

C2 - 24934699

AN - SCOPUS:84907326817

VL - 161

SP - 261

EP - 269

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 4

ER -